ArriVent BioPharma(AVBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVBP ArriVent BioPharma

Market Closed 12-12 16:00:00 EST

24.42

+0.10

+0.41%

盘后24.42

+0.000.00%

16:10 EST

High24.78	Low23.52	Vol209.77K
Open24.36	D1 Closing24.32	Amplitude5.18%
Mkt Cap1.01B	Tradable Cap446.72M	Total Shares41.28M
T/O5.13M	T/O Rate1.15%	Tradable Shares18.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":24.42,"timestamp":1765573200000,"preClose":24.32,"halted":0,"volume":209767,"hourTrading":{"tag":"盘后","latestPrice":24.42,"preClose":24.42,"latestTime":"16:10 EST","volume":16114,"amount":393503.88,"timestamp":1765573803883},"delay":0,"floatShares":18293400,"shares":41281361,"eps":-4.175792,"marketStatus":"Market Closed","change":0.1,"latestTime":"12-12 16:00:00 EST","open":24.36,"high":24.78,"low":23.52,"amount":5127489.027497,"amplitude":0.051809,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.175792,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":24.32,"postHourTrading":{"tag":"盘后","latestPrice":24.42,"preClose":24.42,"latestTime":"16:10 EST","volume":16114,"amount":393503.88,"timestamp":1765573803883},"volumeRatio":0.46003754566097405,"impliedVol":1.7465,"impliedVolPercentile":0.9942},"requestUrl":"/m/hq/s/AVBP","defaultTab":"news","newsList":[{"id":"2590368582","title":"ArriVent BioPharma Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368582","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368582?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:43","pubTimestamp":1765370580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 07:43 ET (12:43 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2590823835","title":"BTIG Initiates ArriVent BioPharma at Buy With $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2590823835","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590823835?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:40","pubTimestamp":1765370459,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) has an average rating of buy and mean price target of $40.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVBP"],"gpt_icon":0},{"id":"2590584948","title":"Arrivent Biopharma Inc : Btig Initiates Coverage With Buy Rating; Price Target $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2590584948","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590584948?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:24","pubTimestamp":1765369464,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG0LZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2590054413","title":"U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590054413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590054413?lang=en_us&edition=fundamental","pubTime":"2025-12-10 14:43","pubTimestamp":1765349009,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer Dec 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including JP Morgan, Pepsi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nL4N3XG0E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","ANF","AZO","BTI","ELAN","CMCSA","IE00BDGV0183.EUR","COF","SG9999011175.SGD","APD","SATS","LU0942090050.USD","LU2746668974.SGD","CF","CAT","BMY","BIIB","BWB","CAPR","LU0321505868.SGD","AMRZ","LU2133065610.SGD","CARR","CMC","CVS","APGE","ASMB","CHD","IE00B894F039.SGD","CPB","DE","IE00B3PB1722.GBP","AVAV","DBI","LU0096364046.USD","ANDE","AU","AMGN","T","CNM","LU1868837136.USD","ASO","IE00B19Z9Z06.USD","LU1868836914.USD","AVBP","PLAY","BLLN","BRZE","CBRL","BDX"],"gpt_icon":1},{"id":"2586408769","title":"ArriVent BioPharma Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2586408769","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586408769?lang=en_us&edition=fundamental","pubTime":"2025-11-26 02:12","pubTimestamp":1764094320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 13:12 ET (18:12 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2586841422","title":"Arrivent Biopharma Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $43","url":"https://stock-news.laohu8.com/highlight/detail?id=2586841422","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586841422?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:11","pubTimestamp":1764069080,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X109O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2586422890","title":"Truist Initiates ArriVent BioPharma at Buy With $43 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2586422890","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586422890?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:10","pubTimestamp":1764069017,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) has an average rating of buy and mean price target of $40.10, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVBP"],"gpt_icon":0},{"id":"1189240324","title":"Stock Track | ArriVent BioPharma Soars 5.21% Ahead of Anticipated Q4 Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1189240324","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189240324?lang=en_us&edition=fundamental","pubTime":"2025-11-13 04:38","pubTimestamp":1762979901,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) saw its stock price surge 5.21% during Wednesday's intraday trading session, as investors position themselves ahead of the company's upcoming fourth-quarter earnings report....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVBP"],"gpt_icon":0},{"id":"1154323013","title":"Stock Track | ArriVent BioPharma Soars 5.21% Ahead of Q4 Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1154323013","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154323013?lang=en_us&edition=fundamental","pubTime":"2025-11-13 04:38","pubTimestamp":1762979899,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) saw its stock price surge 5.21% during Wednesday's trading session, as investors show optimism ahead of the company's upcoming fourth-quarter earnings report. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVBP"],"gpt_icon":0},{"id":"2582327400","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2582327400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582327400?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:00","pubTimestamp":1762945200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CI&T Inc. Class A                               3Q       .10        AMC. ·Digi Intl Inc.                                  4Q       .51    4:00 PM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANNX","RSKD","ABOS","AFYA","ARDT","CPRT","ALUR","ABSI","ASND","AEBI","AUTL","GUTS","TWFG","AMAT","AVBP","BLDP","AFCG","ATAT","IMRX","ALH","CRMD","CINT","IBTA","ALC","AEMD","CSCO","ABEO","ARCO","CELC","BABA","ALVO","CREX","AKRO","AIRG","BEEM","PYPD","CABA","ARX","CURI","CLBT","ATXS","CCAP","MGX","ALMS","CRMT","ACXP","CAAP","LUNG","AYTU"],"gpt_icon":1},{"id":"2582390854","title":"ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2582390854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582390854?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:15","pubTimestamp":1762895740,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their bullish stance on AVBP stock, giving a Buy rating today. Soumit Roy has given his Buy rating d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-inc-strategic-advancements-and-promising-developments-drive-buy-rating-with-45-price-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-inc-strategic-advancements-and-promising-developments-drive-buy-rating-with-45-price-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"gpt_icon":0},{"id":"2582392082","title":"ArriVent BioPharma Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2582392082","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582392082?lang=en_us&edition=fundamental","pubTime":"2025-11-12 04:45","pubTimestamp":1762893900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 15:45 ET (20:45 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"1146695105","title":"Stock Track | ArriVent BioPharma Soars 5.05% on Pipeline Updates and Bullish Analyst Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1146695105","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146695105?lang=en_us&edition=fundamental","pubTime":"2025-11-12 02:58","pubTimestamp":1762887501,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) saw its stock soar 5.05% in intraday trading on Tuesday, as investors responded positively to the company's latest pipeline updates and a reaffirmed bullish analyst rating....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVBP"],"gpt_icon":0},{"id":"1116309141","title":"Stock Track | ArriVent BioPharma Soars 5.05% on Strong Pipeline Update and Analyst Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1116309141","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116309141?lang=en_us&edition=fundamental","pubTime":"2025-11-12 02:58","pubTimestamp":1762887499,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) saw its stock soar 5.05% in intraday trading on Tuesday, following a series of positive developments for the company. The surge comes on the heels of a comprehensive update...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVBP"],"gpt_icon":0},{"id":"2582671793","title":"ArriVent Biopharma Showcases Global Oncology Pipeline and Late-Stage Firmonertinib Program in New Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2582671793","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582671793?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:39","pubTimestamp":1762871941,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma Inc. has outlined updates on its global oncology pipeline, highlighting its lead program, firmonertinib, which has received Breakthrough Therapy Designation for first-line treatment of EGFR Exon 20 insertion mutant non-small cell lung cancer . The company expects topline results from a registrational study in early 2026 and is expanding firmonertinib into a pivotal trial for first-line EGFR PACC mutant NSCLC, supported by positive clinical data. ArriVent is also advancing its next-generation antibody-drug conjugate  portfolio, with ARR-217 currently in Phase 1 trials for gastrointestinal tumors and additional ADC programs expected to enter clinical development in 2026. The pipeline includes multiple programs in various stages targeting solid tumors and NSCLC, with global development efforts outside China. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDLc2DYDJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2582365139","title":"H.C. Wainwright Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582365139","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582365139?lang=en_us&edition=fundamental","pubTime":"2025-11-11 19:56","pubTimestamp":1762862190,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on ArriVent BioPharma, Inc., with a price target of $42.00. A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-arrivent-biopharma-inc-avbp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-arrivent-biopharma-inc-avbp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"gpt_icon":0},{"id":"2582339086","title":"ArriVent BioPharma Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582339086","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582339086?lang=en_us&edition=fundamental","pubTime":"2025-11-11 12:27","pubTimestamp":1762835260,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc. ( ($AVBP) ) has released its Q3 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to its...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2582938254","title":"ArriVent BioPharma’s Promising Trial Results and Strategic Developments Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2582938254","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582938254?lang=en_us&edition=fundamental","pubTime":"2025-11-11 08:25","pubTimestamp":1762820711,"startTime":"0","endTime":"0","summary":"Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on ArriVent BioPharma, Inc.. The associated price target was lowered to $36...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-biopharmas-promising-trial-results-and-strategic-developments-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-biopharmas-promising-trial-results-and-strategic-developments-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"gpt_icon":0},{"id":"2582797808","title":"ArriVent BioPharma Q3 EPS $(0.83) Misses $(0.81) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582797808","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582797808?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:05","pubTimestamp":1762779931,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.81) by 2.85 percent. This is a 36.07 percent decrease over losses of $(0.61) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48749577/arrivent-biopharma-q3-eps-0-83-misses-0-81-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2582879755","title":"ArriVent Biopharma Appoints Brent S. Rice as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879755","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879755?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:03","pubTimestamp":1762779809,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma Inc. has appointed Brent S. Rice as Chief Commercial Officer. Rice joins the company with over 25 years of commercial experience in the biotechnology and pharmaceutical industry, most recently serving as Senior Vice President and global Chief Commercial Officer at Autolus Therapeutics Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL5xDT0P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://arrivent.com","stockEarnings":[{"period":"1week","weight":-0.0109},{"period":"1month","weight":0.2089},{"period":"3month","weight":0.239},{"period":"6month","weight":0.0494},{"period":"1year","weight":-0.0564},{"period":"ytd","weight":-0.0833}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.","exchange":"NASDAQ","name":"ArriVent BioPharma","nameEN":"ArriVent BioPharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ArriVent BioPharma(AVBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ArriVent BioPharma(AVBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ArriVent BioPharma,AVBP,ArriVent BioPharma股票,ArriVent BioPharma股票老虎,ArriVent BioPharma股票老虎国际,ArriVent BioPharma行情,ArriVent BioPharma股票行情,ArriVent BioPharma股价,ArriVent BioPharma股市,ArriVent BioPharma股票价格,ArriVent BioPharma股票交易,ArriVent BioPharma股票购买,ArriVent BioPharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ArriVent BioPharma(AVBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ArriVent BioPharma(AVBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}